Literature DB >> 25475555

TWIST1 is a direct transcriptional target of MYCN and MYC in neuroblastoma.

Abdelkader Selmi1, Maud de Saint-Jean1, Anne-Catherine Jallas2, Elisabeth Garin2, Michael D Hogarty3, Jean Bénard4, Alain Puisieux5, Aurélien Marabelle6, Sandrine Valsesia-Wittmann7.   

Abstract

In neuroblastoma, MYCN amplification is associated with a worse prognosis and is a criterion used in the clinic to provide intensive treatments to children even with localized disease. In correlation with MYCN amplification, upregulation of TWIST1, a transcription factor playing a crucial role in inhibition of apoptosis and differentiation, was previously reported. Clinical data set analysis of MYCN, MYC and TWIST1 expression permits us to confirm that TWIST1 expression is upregulated in MYCN amplified neuroblastoma but also in a subset of neuroblastoma harboring high expression of MYCN or MYC without gene amplification. In silico analyses reveal the presence of several MYC regulatory motifs (E-Boxes and INR) within the TWIST1 promoter. Using gel shift assay and reporter activity assays, we demonstrate that both N-Myc and c-Myc proteins can bind and activate the TWIST1 promoter. Therefore, we propose TWIST1 as a direct MYC transcriptional target.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  MYC; MYCN; TWIST1; Transcriptional regulation neuroblastoma

Mesh:

Substances:

Year:  2014        PMID: 25475555     DOI: 10.1016/j.canlet.2014.11.056

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  22 in total

1.  The T-Box factor TBX3 is important in S-phase and is regulated by c-Myc and cyclin A-CDK2.

Authors:  Tarryn Willmer; Jade Peres; Shaheen Mowla; Amaal Abrahams; Sharon Prince
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

2.  Reactivation of TWIST1 contributes to Ewing sarcoma metastasis.

Authors:  Sun Choo; Ping Wang; Robert Newbury; William Roberts; Jing Yang
Journal:  Pediatr Blood Cancer       Date:  2017-09-05       Impact factor: 3.167

3.  RRM2 enhances MYCN-driven neuroblastoma formation and acts as a synergistic target with CHK1 inhibition.

Authors:  Carolina Nunes; Lisa Depestel; Liselot Mus; Kaylee M Keller; Louis Delhaye; Amber Louwagie; Muhammad Rishfi; Alex Whale; Neesha Kara; Simon R Andrews; Filemon Dela Cruz; Daoqi You; Armaan Siddiquee; Camila Takeno Cologna; Sam De Craemer; Emmy Dolman; Christoph Bartenhagen; Fanny De Vloed; Ellen Sanders; Aline Eggermont; Sarah-Lee Bekaert; Wouter Van Loocke; Jan Willem Bek; Givani Dewyn; Siebe Loontiens; Gert Van Isterdael; Bieke Decaesteker; Laurentijn Tilleman; Filip Van Nieuwerburgh; Vanessa Vermeirssen; Christophe Van Neste; Bart Ghesquiere; Steven Goossens; Sven Eyckerman; Katleen De Preter; Matthias Fischer; Jon Houseley; Jan Molenaar; Bram De Wilde; Stephen S Roberts; Kaat Durinck; Frank Speleman
Journal:  Sci Adv       Date:  2022-07-13       Impact factor: 14.957

4.  Far upstream element-binding protein 1 is a prognostic biomarker and promotes nasopharyngeal carcinoma progression.

Authors:  Z-H Liu; J-L Hu; J-Z Liang; A-J Zhou; M-Z Li; S-M Yan; X Zhang; S Gao; L Chen; Q Zhong; M-S Zeng
Journal:  Cell Death Dis       Date:  2015-10-15       Impact factor: 8.469

5.  Unveiling MYCN regulatory networks in neuroblastoma via integrative analysis of heterogeneous genomics data.

Authors:  Chia-Lang Hsu; Hsin-Yi Chang; Jen-Yun Chang; Wen-Ming Hsu; Hsuan-Cheng Huang; Hsueh-Fen Juan
Journal:  Oncotarget       Date:  2016-06-14

Review 6.  The MYCN Protein in Health and Disease.

Authors:  María Victoria Ruiz-Pérez; Aine Brigette Henley; Marie Arsenian-Henriksson
Journal:  Genes (Basel)       Date:  2017-03-30       Impact factor: 4.096

7.  Chromosome band 11q23 deletion predicts poor prognosis in bone marrow metastatic neuroblastoma patients without MYCN amplification.

Authors:  Zhi-Xia Yue; Tian-Yu Xing; Chao Gao; Shu-Guang Liu; Wen Zhao; Qian Zhao; Xi-Si Wang; Mei Jin; Xiao-Li Ma
Journal:  Cancer Commun (Lond)       Date:  2019-11-04

Review 8.  Targeting the p53-MDM2 pathway for neuroblastoma therapy: Rays of hope.

Authors:  Atif Zafar; Wei Wang; Gang Liu; Wa Xian; Frank McKeon; Jia Zhou; Ruiwen Zhang
Journal:  Cancer Lett       Date:  2020-09-29       Impact factor: 8.679

9.  Prognostic and clinicopathological value of Twist expression in breast cancer: A meta-analysis.

Authors:  Weiqiang Qiao; Zhiqiang Jia; Heyang Liu; Qipeng Liu; Ting Zhang; Wanying Guo; Peng Li; Miao Deng; Sanqiang Li
Journal:  PLoS One       Date:  2017-10-09       Impact factor: 3.240

Review 10.  AKT-ions with a TWIST between EMT and MET.

Authors:  Huifang Tang; Daniela Massi; Brian A Hemmings; Mario Mandalà; Zhengqiang Hu; Andreas Wicki; Gongda Xue
Journal:  Oncotarget       Date:  2016-09-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.